Last $1.29 USD
Change Today -0.04 / -3.01%
Volume 1.1M
PPHM On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

peregrine pharmaceuticals (PPHM) Snapshot

Open
$1.33
Previous Close
$1.33
Day High
$1.37
Day Low
$1.28
52 Week High
03/6/14 - $3.18
52 Week Low
10/10/14 - $1.27
Market Cap
234.9M
Average Volume 10 Days
855.8K
EPS TTM
$-0.27
Shares Outstanding
182.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PEREGRINE PHARMACEUTICALS (PPHM)

peregrine pharmaceuticals (PPHM) Related Businessweek News

No Related Businessweek News Found

peregrine pharmaceuticals (PPHM) Details

Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States. Its lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small cell lung cancer along with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also evaluating its lead molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of various solid tumor types. In addition, it provides contract manufacturing services ranging from cell line development to commercial current good manufacturing practice biomanufacturing to third-party clients. The company has various license agreements with the University of Texas Southwestern Medical Center at Dallas; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; Lonza Biologics; Affitech A/S; and Merck KGaA. Peregrine Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Tustin, California.

180 Employees
Last Reported Date: 07/14/14
Founded in 1981

peregrine pharmaceuticals (PPHM) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $557.7K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $423.6K
Vice President, General Counsel and Corporate...
Total Annual Compensation: $393.8K
Vice President of Intellectual Property
Total Annual Compensation: $364.7K
Vice President of Clinical & Regulatory Affai...
Total Annual Compensation: $338.0K
Compensation as of Fiscal Year 2014.

peregrine pharmaceuticals (PPHM) Key Developments

Peregrine Pharmaceuticals, Inc. Presents Phase II Clinical Data of its Bavituximab at American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Peregrine Pharmaceuticals, Inc. announced the presentation of clinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. This conference is being held January 15-17, 2015 at the Moscone West Convention Center in San Francisco, California. A Phase II Study of Bavituximab and Sorafenib in Advanced Hepatocellular Carcinoma (HCC) will be presented this afternoon by Adam Yopp, M.D., assistant professor of surgery at the University of Texas Southwestern Medical Center Dallas, Texas. In this single-center, single-arm, open-label investigator-sponsored trial (IST), 38 patients with advanced HCC received bavituximab (3mg/kg) weekly and sorafenib (400 mg) twice daily until disease progression or toxicity. Data show that the combination of bavituximab and sorafenib is associated with an improved time to progression (TTP) of 6.7 months, a disease specific survival (DSS) of 8.7 months, a disease control rate (DCR) of 58% (22 out of 38 patients) and a 4-month progression-free survival (PFS) of 62%. Two patients (5%) achieved a partial response according to Response Evaluation Criteria In Solid Tumors (RECIST). The secondary endpoint of median overall survival (OS) was 6.2 months. The combination of bavituximab and sorafenib was well-tolerated in patients with advanced HCC with no indications of autoimmune adverse events that have been seen with other checkpoint immunotherapies. Recently presented translational data of six patients from this trial show that half of the patients evaluated had an increase in tumor fighting immune cells following one cycle of bavituximab treatment, similar to what has been shown for PS-targeting antibodies in multiple preclinical cancer models. In addition, the increase in immune response was associated with patients that remained on study treatment for longer time periods, suggesting the possibility of a clinically meaningful anti-tumor immune response. Three of the six patients evaluated had increased infiltration of activated tumor-fighting T-cells (CD8) into the tumor microenvironment which correlated with a prolonged time to disease progression. In addition, these responding patients initially expressed lower levels of PD-1 positive cells, an established marker of T-cell activation and disease outcome, prior to the initiation of therapy that was followed by a measurable rise post bavituximab treatment. In this Phase II non-randomized, open-label trial, 38 patients with advanced HCC received bavituximab weekly and sorafenib (400 mg) twice daily, until disease progression or toxicity. The primary endpoint of this trial is radiologic time to progression with imaging occurring at 6 week intervals. Secondary endpoints of this trial include overall survival (OS), progression free survival (PFS), safety and response rates. In order to leverage recent understandings surrounding the immune-stimulatory mechanism of action of bavituximab, several additional components have been installed into this portion of the trial. These include plasma and serum collection and tissue biopsies for evaluating changes in immune response following bavituximab treatment to assess whether combination therapy reactivates tumor immunity by changing the tumor microenvironment from immunosuppressive to immunoreactive by changing the tumor infiltrating cell composition or inducing T-cell response to tumor antigens.

Peregrine Pharmaceuticals, Inc. Announces Preclinical Data from Recently Conducted Single Agent Studies at 2014 San Antonio Breast Cancer Symposium in San Antonio, Texas

Peregrine Pharmaceuticals, Inc. announced preclinical data from recently conducted single agent studies at the 2014 San Antonio Breast Cancer Symposium in San Antonio, Texas being held December 9-13, 2014. In a poster titled ‘Antibody-mediated Blockade of Phosphatidylserine Enhances the Anti-tumor Activity of Immune Checkpoint Inhibitor a-PD-1 by Affecting Myeloid Derived Suppressor Cells (MDSC) and Lymphocyte Populations in a Breast Tumor Microenvironment,’ newly published data show that ch1N11, the preclinical equivalent to bavituximab, as a single agent, demonstrated statistically significant (p=0.025) tumor growth inhibition in mice bearing EMT-6 breast tumors when compared to a control antibody. In addition, researchers using fluorescence-activated cell sorting (FACS) found that the single agent treatment of tumor bearing mice with ch1N11 yielded statistically significant increases in the percentage of CD4 (p=0.016) and CD8 (p=0.018) tumor infiltrating lymphocytes and decreases tumor MDSC/CD4 (p=0.026) and MDSC/CD8 (p=0.014) ratios, all key indicators of stimulating immune activation.

Peregrine Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended October 31, 2014; Provides Contract Manufacturing Revenue Guidance for the Fiscal Year 2015

Peregrine Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter ad six months ended October 31, 2014. For the quarter, the company reported total revenues of $6,300,000 against $7,354,000 a year ago. Loss from operations was $12,137,000 against $7,814,000 a year ago. Net loss was $12,100,000 against $7,790,000 a year ago. Net loss attributable to common stockholders was $13,131,000 against $7,790,000 a year ago. Basic and diluted loss per common share was $0.07 against $0.05 a year ago. For the six months, the company reported total revenues of $11,796,000 against $12,042,000 a year ago. Loss from operations was $25,308,000 against $15,434,000 a year ago. Net loss was $25,229,000 against $15,390,000 a year ago. Net loss attributable to common stockholders was $27,031,000 against $15,390,000 a year ago. Basic and diluted loss per common share was $0.15 against $0.10 a year ago. For the fiscal year 2015, the company expects contract manufacturing revenue to be between $19 and $23 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PPHM:US $1.29 USD -0.04

PPHM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $9.16 USD -0.73
Dynavax Technologies Corp $17.01 USD -1.09
GenVec Inc $3.43 USD -0.01
Inovio Pharmaceuticals Inc $8.50 USD -0.44
Vical Inc $1.03 USD 0.00
View Industry Companies
 

Industry Analysis

PPHM

Industry Average

Valuation PPHM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.8x
Price/Book 4.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PEREGRINE PHARMACEUTICALS, please visit www.peregrineinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.